Apellis Pharmaceuticals Stock Surges 139%, With A 5-Day Winning Spree
Apellis Pharmaceuticals (NASDAQ: APLS) stock has surged by 139% over the past five trading days. This marks a significant winning streak for the company's shares. The article title highlights this impressive short-term performance.
Biogen Discloses Tender Offer at Apellis with 14.2% Stake
Biogen Inc. has disclosed a 14.2% beneficial stake in Apellis Pharmaceuticals, Inc. through a tender and support agreement, aiming to acquire and take Apellis private. Biogen plans to launch a tender offer for all Apellis shares at $41.00 cash per share plus a contingent value right, with the acquisition expected to close in the second quarter of 2026. The deal, supported by key Apellis holders, will be financed with cash on hand and a term loan, and will bypass a stockholder vote under Delaware law.
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending
Biogen's subsidiary, Aspen Purchaser Sub, Inc., has announced its plan to launch a tender offer to acquire all outstanding shares of Apellis Pharmaceuticals (APLS) under an Agreement and Plan of Merger dated March 31, 2026. This pre-commencement communication, filed as an SC TO-C form, indicates that the formal tender offer has not yet begun and advises Apellis shareholders to await and carefully review the forthcoming offer materials on Schedule TO and the solicitation/recommendation statement on Schedule 14D-9. The filing does not disclose the terms or pricing of the tender offer, which will be detailed in subsequent documents.
Comparing Apellis Pharmaceuticals With Industry Competitors In Biotechnology Industry
This article compares Apellis Pharmaceuticals (NASDAQ: APLS) with its biotechnology industry peers, analyzing financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. While Apellis shows potential undervaluation based on its P/S ratio, other indicators suggest overvaluation and weaker financial performance, including a high debt-to-equity ratio, compared to its competitors. The analysis aims to provide investors with insights into the company's standing within the competitive biotechnology sector.
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?
Apellis Pharmaceuticals (APLS) saw its shares surge 135.4% after Biogen announced a $5.6 billion acquisition deal, representing an 86% premium and additional contingent payments tied to Syfovre sales. Despite the immediate stock jump, a negative trend in earnings estimate revisions and a Zacks Rank #3 (Hold) suggest investors should monitor future performance. The acquisition highlights the strong commercial potential of Apellis's drugs, Empaveli and Syfovre.
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to Biogen Inc. KSF is scrutinizing whether the offer of $41.00 per share in cash plus a contingent value right for SYFOVRE sales adequately values Apellis, and is inviting shareholders to contact them to discuss their legal rights. The firm notes that the transaction is structured as a tender offer, implying that time is of the essence for shareholders to act.
Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Apellis Pharmaceuticals Inc. regarding its recently announced transaction with Biogen, questioning if public shareholders are receiving a fair price. The investigation focuses on whether the Apellis board fulfilled its fiduciary duties, citing concerns about the $41 per share offer, contingent value rights, and transaction limitations on competing bids. Apellis stockholders are encouraged to join the investigation.
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by SG Americas Securities LLC
SG Americas Securities LLC significantly increased its stake in Apellis Pharmaceuticals Inc. ($APLS) by 35.9% in Q4, now holding 567,046 shares valued at $14.24 million. Apellis exceeded EPS estimates, reporting $0.47 against a -$0.39 consensus, although revenue was down 5.9% year-over-year. The stock holds a "Moderate Buy" consensus rating from analysts, with a target price of $32.42, while trading near $16.97.
(APLS) Volatility Zones as Tactical Triggers
This article from Stock Traders Daily discusses volatility zones for Apellis Pharmaceuticals Inc. (APLS), highlighting divergent sentiment across all horizons and elevated downside risk. It provides specific institutional trading strategies including a position trading strategy, a momentum breakout strategy, and a risk hedging strategy with detailed entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis for near-term, mid-term, and long-term outlooks.
Is It Time To Reconsider Apellis Pharmaceuticals (APLS) After Its Recent Share Price Slump?
Apellis Pharmaceuticals (APLS) has seen significant share price declines recently, making its current price of US$17.64 potentially interesting. A Discounted Cash Flow (DCF) analysis suggests the stock is 84.7% undervalued, with an intrinsic value of $115.07 per share. However, its Price-to-Earnings (P/E) ratio of 100.7x is well above the biotech industry average and Simply Wall St's proprietary Fair Ratio of 32.6x, indicating it is overvalued on this measure.
Vanguard disaggregates holdings; APLS shows 0 shares (APLS)
The Vanguard Group filed an amended Schedule 13G/A for Apellis Pharmaceuticals, Inc. (APLS), reporting 0 shares beneficially owned and 0% ownership of Common Stock. This change follows an internal realignment by Vanguard effective January 12, 2026, which disaggregates reporting such that certain subsidiaries will now report beneficial ownership separately. The filing indicates that while The Vanguard Group itself no longer holds beneficial ownership according to this document, its subsidiaries may still hold APLS shares and will report them independently.
Why Is Apellis Pharmaceuticals (APLS) Down 17.3% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) shares have dropped 17.3% since its last earnings report, underperforming the S&P 500. The company reported a wider-than-expected Q4 2025 loss but total revenues beat estimates, largely driven by Syfovre and Empaveli sales, despite a year-over-year decline in Syfovre revenues. While estimates have trended upward, the stock currently holds a Zacks Rank #3 (Hold).
APLS SEC Filings - Apellis Pharmace 10-K, 10-Q, 8-K Forms
This page provides access to Apellis Pharmaceuticals (APLS) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights recent insider stock sales by executives and officers, primarily to cover tax withholdings on restricted stock units. The page also offers AI-powered summaries of these filings and basic company stock data.
APLS SEC Filings - Apellis Pharmace 10-K, 10-Q, 8-K Forms
This article provides a comprehensive overview of Apellis Pharmaceuticals (APLS) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights key financial performance data, such as Q2-25 revenue and net loss, and significant events like the Royalty Buy-Down Agreement with Sobi, which infused $275 million in cash. The article also details recent insider transactions from executives and beneficial ownership reports, offering investors insights into company activities and financial health.
Apellis Pharmaceuticals, Inc. (APLS) surpasses Q4 earnings and revenue estimates
Apellis Pharmaceuticals (APLS) announced robust Q4 2025 results, exceeding both earnings and revenue expectations. The company reported adjusted earnings of $0.08 per share against an anticipated loss, and revenues significantly surpassed estimates, driven by strong sales of its flagship drug, Syfovre. This positive financial performance indicates a strong operational quarter for Apellis.
Apellis Pharmaceuticals, Inc. $APLS Holdings Cut by Hudson Bay Capital Management LP
Hudson Bay Capital Management LP reduced its stake in Apellis Pharmaceuticals (NASDAQ:APLS) by 11.9% in the third quarter of last year. Despite this cut and recent insider selling, institutional investors maintain substantial ownership, and analysts hold a "Moderate Buy" consensus with a target price of $32.42. The company recently exceeded quarterly EPS estimates and slightly missed revenue expectations.
Complement 3 Glomerulopathy Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma
The Complement 3 Glomerulopathy (C3G) market is projected for strong growth through 2034, driven by increasing prevalence and the launch of pipeline products from companies like NovelMed Therapeutics, Apellis Pharmaceuticals, and Novartis. Significant clinical trial successes, such as Apellis's Empaveli and Novartis's Fabhalta, are transforming the treatment landscape for this rare kidney disorder. The market, valued at approximately USD 35 million in 2023, is expected to expand considerably as new therapies target the abnormal activation of the complement system.
Apellis Pharmaceuticals, Inc. (APLS) surpasses Q4 earnings and revenue estimates
Apellis Pharmaceuticals (APLS) reported stronger-than-expected financial results for the fourth quarter, with adjusted earnings per share of $0.05 against an anticipated loss of $0.04. The company also exceeded revenue forecasts, achieving $114.37 million compared to an estimated $111.45 million. Notably, its drug SYFOVRE, for geographic atrophy (GA), generated $84.5 million in product revenue and expanded its market share, becoming a leading treatment option in the wet age-related macular degeneration and GA space.
Integral Health Asset Management LLC Purchases Shares of 250,000 Apellis Pharmaceuticals, Inc. $APLS
Integral Health Asset Management LLC has acquired 250,000 shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) for approximately $5.66 million, establishing a new position in the company. Despite recent insider selling by the CEO and other insiders totaling about $2.6 million, Apellis Pharmaceuticals exceeded Q3 earnings expectations, reporting an EPS of $0.47 against estimated -$0.39 and revenue of $199.9 million. Institutional investors currently hold a significant 96.29% ownership in the company.
Price-Driven Insight from (APLS) for Rule-Based Strategy
This article provides a price-driven analysis for Apellis Pharmaceuticals Inc. (APLS), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. The report warns of elevated downside risk due to a lack of additional long-term support signals.
Bank of Nova Scotia Acquires 861,413 Shares of Apellis Pharmaceuticals, Inc. $APLS
Bank of Nova Scotia significantly increased its stake in Apellis Pharmaceuticals (NASDAQ:APLS) by 144.8% in the third quarter, acquiring an additional 861,413 shares to hold a total of 1,456,225 shares valued at approximately $32.95 million. Apellis Pharmaceuticals reported stronger-than-expected quarterly earnings, with an EPS of $0.47 and revenue of $199.91 million. The company currently holds a "Moderate Buy" consensus rating from analysts, with an average target price of $32.63.
Does Apellis Pharmaceuticals' (APLS) New Board Member Reveal a Deeper R&D Commercialization Strategy Shift?
Apellis Pharmaceuticals has appointed Mikael Dolsten, former chief scientific officer of Pfizer, to its board of directors, signaling a potential shift in its R&D commercialization strategy. This move is seen as additive to Apellis's scientific and development depth, especially regarding Empaveli's potential in rare kidney diseases, and could influence market perception and analyst forecasts for its key products, Empaveli and Syfovre. Despite this, the company still faces challenges related to pricing, access, and competition, particularly the strain from free drug usage and co-pay funding limits.
Does Apellis Pharmaceuticals' (APLS) New Board Member Reveal a Deeper R&D Commercialization Strategy Shift?
Apellis Pharmaceuticals appointed Mikael Dolsten, former Pfizer chief scientific officer, to its board, signaling a potential focus on enhancing its R&D commercialization strategy. This move is particularly relevant for the future of Apellis's Empaveli drug, especially for upcoming kidney indications, despite near-term pressures on its existing products. Analysts see a potential for significant upside in Apellis's stock, with revenue and earnings growth projected by 2028.
Apellis wins new buy at Roth on Syfovre prospects
Roth MKM initiated coverage on Apellis Pharmaceuticals with a Buy rating, citing confidence in the growth potential of Syfovre, its treatment for geographic atrophy. The firm believes that underappreciated aspects of Syfovre's commercial launch and the company's financial strength will drive significant upside in Apellis shares.
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by HighVista Strategies LLC
HighVista Strategies LLC increased its holdings in Apellis Pharmaceuticals (NASDAQ:APLS) by 68.2%, acquiring an additional 59,066 shares, bringing its total to 145,729 shares valued at approximately $3.30 million. Apellis Pharmaceuticals recently reported strong quarterly earnings, beating EPS expectations with $0.47 per share against a -$0.39 consensus, although revenue was down 5.9% year-over-year. The company trades with a market capitalization of $2.42 billion and has a consensus analyst rating of "Moderate Buy" with an average target price of $32.63.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Moderate Buy" from Brokerages
Apellis Pharmaceuticals (NASDAQ: APLS) has received a consensus "Moderate Buy" rating from 22 brokerages, with an average 1-year price target of $32.63. Despite recent insider share sales totaling $2.61 million, insiders still hold 6.8% of the company. The biopharmaceutical company reported strong quarterly earnings, beating analyst estimates with $0.47 EPS and $199.9 million in revenue.
Assessing Apellis Pharmaceuticals (APLS) Valuation After Weaker Returns And EMPAVELI Label Expansion
Apellis Pharmaceuticals (APLS) has seen weaker stock performance recently, with negative returns over the past month, three months, and year, despite generating $1 billion in revenue and $22.39 million in net income. The company's fair value is estimated at $33.95 per share, significantly above its current trading price of $18.94, driven by expectations of long-term growth from EMPAVELI's label expansion. However, the market's current P/E ratio for APLS is much higher than its peers, raising questions about the optimism of future earnings growth.
Apellis (NASDAQ: APLS) CEO gifts 129,738 shares via family trusts
Apellis Pharmaceuticals CEO Cedric Francois reported two bona fide gift transactions of 129,738 common shares to family trusts on March 11, 2026. These transactions, coded as gifts at $0.00 per share, did not involve open-market sales. Following these transfers, Francois directly holds 425,968 shares and maintains substantial indirect holdings through various trusts.
Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Roth Mkm
Roth Mkm initiated coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a "Buy" rating and a $31.00 price target, suggesting a potential 65% upside. The company recently reported strong quarterly EPS of $0.47 against a consensus loss, although revenue decreased year-over-year. Despite recent insider selling, institutional investors hold a significant majority of the stock.
Here is Why JPMorgan is Overweight on Apellis Pharma (APLS)
JPMorgan analyst Anupam Rama increased the price target for Apellis Pharmaceuticals Inc. (APLS) from $36 to $37, reiterating an "Overweight" rating due to optimistic survey results for their Empaveli prescription medication. This decision comes despite a recent price target reduction by Wedbush from $20 to $18, which maintained a "Neutral" rating. Apellis Pharmaceuticals focuses on treatments for rare blood disorders and eye conditions and has several innovative treatments in development.
Here is Why JPMorgan is Overweight on Apellis Pharma (APLS)
JPMorgan has reiterated an "Overweight" rating and increased the price target for Apellis Pharmaceuticals Inc. (APLS) from $36 to $37, suggesting an 84% upside. This decision follows a survey indicating strong market potential for Apellis's Empaveli. Meanwhile, Wedbush adjusted its price target down from $20 to $18, maintaining a "Neutral" rating, citing that Q4 results met expectations and management foresees flat Syfovre pricing through fiscal year 2026.
Assessing Apellis Pharmaceuticals (APLS) Valuation As Long Term Returns Lag And P/E Diverges From Biotech Peers
Apellis Pharmaceuticals (APLS) is currently valued by analysts as 40.9% undervalued with a fair value of $33.95, based on projections of increasing revenue and profitability from new indications like rare kidney diseases. However, the company's current P/E ratio of 114.6x significantly diverges from the US biotech industry average of 21x and a fair ratio of 32.8x, suggesting potential valuation risk for earnings-focused investors. Long-term shareholders have seen declines of 20.2% over one year and 68% over three years, indicating soft performance despite recent momentum.
How Apellis Adding Ex-Pfizer R&D Chief Mikael Dolsten to Its Board Will Impact Apellis (APLS) Investors
Apellis Pharmaceuticals announced that Mikael Dolsten, former Pfizer chief scientific officer, has joined its board of directors, expected to influence investor assessment of Apellis's R&D and commercialization capabilities. While Dolsten's expertise in R&D and regulatory paths is seen as beneficial, the company's near-term profitability remains highly dependent on its core products, SYFOVRE and EMPAVELI, and a high valuation makes it susceptible to slowdowns or setbacks despite recent profitability. The article suggests investors consider other fair value estimates and research for a comprehensive understanding of the company's financial health.
How Apellis Adding Ex-Pfizer R&D Chief Mikael Dolsten to Its Board Will Impact Apellis (APLS) Investors
Apellis Pharmaceuticals has appointed Mikael Dolsten, former Pfizer chief scientific officer, to its board of directors, a move that could significantly influence the company's R&D and regulatory strategies. Dolsten's extensive experience adds credibility to Apellis's long-term growth plans, particularly in eye and rare kidney diseases, though short-term success remains dependent on core product uptake and managing financial risks. Investors will need to weigh Dolsten's impact against the company's recent profitability and high valuation, considering potential pricing pressures and reimbursement trends.
Apellis Adds Ex Pfizer R&D Chief To Board As Growth Plans Evolve
Apellis Pharmaceuticals has appointed Dr. Mikael Dolsten, former Pfizer CSO, to its board of directors, aiming to leverage his extensive experience in pharmaceutical R&D and drug approvals. This move is expected to strengthen Apellis's governance, scientific oversight, and pipeline development, especially as the company focuses on late-stage programs and label expansions after reporting strong 2025 revenues. Investors are advised to consider the potential benefits of his expertise in navigating regulatory processes and broadening partnerships, alongside the potential risks associated with board members holding multiple roles and a large pharma decision-making style.
(APLS) Price Dynamics and Execution-Aware Positioning
This article analyzes Apellis Pharmaceuticals Inc. (APLS) stock, highlighting a weak near and mid-term sentiment despite a positive long-term outlook. Key findings include a 70.8:1 risk-reward setup targeting a 21.9% gain, and offers three AI-generated trading strategies tailored for different risk profiles. The analysis emphasizes execution-aware positioning based on multi-timeframe signal analysis.
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $37.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co. raised its price target for Apellis Pharmaceuticals (NASDAQ:APLS) to $37.00 from $36.00, maintaining an "overweight" rating and suggesting a potential 83.62% upside. Analyst opinions are divided with a consensus "Hold" rating and an average target of $32.72. The company recently surpassed EPS expectations but saw a slight year-over-year revenue decline, while institutional investors hold a significant portion of its shares.
Apellis Adds Ex Pfizer R&D Chief To Board As Growth Plans Evolve
Apellis Pharmaceuticals has appointed Dr. Mikael Dolsten, a former chief scientific officer at Pfizer, to its board of directors. This appointment brings extensive R&D and drug approval experience from large pharma to Apellis, which focuses on complement system therapies. Investors should consider how Dolsten's background might influence Apellis's pipeline, partnerships, and risk management, noting both the potential benefits for regulatory interactions and the possible impact of a more conservative approach to R&D.
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $20.00 at Mizuho
Mizuho has increased its price target for Apellis Pharmaceuticals (NASDAQ:APLS) to $20.00 from $19.00, maintaining a "neutral" rating. This adjustment comes after Apellis reported stronger-than-expected quarterly EPS of $0.47, surpassing estimates of -$0.39, despite a 5.9% year-over-year revenue decrease. The company currently holds an average analyst rating of "Hold" with a target price of $32.67, indicating significant divergence among analysts.
Assessing Apellis Pharmaceuticals: Insights From 11 Financial Analysts
Eleven financial analysts have provided their assessments of Apellis Pharmaceuticals (NASDAQ: APLS) over the past quarter, with an average 12-month price target of $30.91, down from $33.10. The company faces challenges in revenue growth and asset utilization but shows strong net margins. Analysts' actions, ratings, and price targets reflect their evolving perspectives on the company's market position and financial health.
Apellis Pharmaceuticals (APLS) director receives new stock options and RSUs
Apellis Pharmaceuticals director Mikael Dolsten received new equity awards, including stock options for 24,135 shares at an exercise price of $20.96, vesting over three years. He also received a grant of 14,312 restricted stock units, which will fully vest on the first anniversary of the grant date or upon his termination of service as a director, provided he continues to serve. These grants were reported on February 27, 2026, via an SEC Form 4 filing.
Apellis (APLS) director Mikael Dolsten submits initial Form 3 insider filing
Mikael Dolsten, a new director at Apellis Pharmaceuticals, Inc. (APLS), has filed an initial Form 3 insider filing. This filing establishes him as an insider for disclosure purposes, but it does not indicate any stock transactions or changes in his beneficial ownership. The Form 3 confirms his role as a director and signifies his future obligation to report insider transactions.
Apellis Pharmaceuticals (Nasdaq:APLS) - Stock Analysis
This Simply Wall St analysis of Apellis Pharmaceuticals (APLS) indicates the stock is trading significantly below its estimated fair value. While the company demonstrates strong future growth potential with earnings forecast to increase by 53.91% annually, it also faces risks including significant insider selling and reliance on two core products. The report provides an overview of APLS's financial health, past performance, and recent news, alongside analyst price targets and community narratives offering varied perspectives on its future.
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
Apellis Pharmaceuticals, Inc. announced that Mikael Dolsten, M.D., Ph.D., has joined its board of directors. Dr. Dolsten previously served as chief scientific officer at Pfizer, overseeing the approval of over 36 medicines and vaccines. He brings extensive pharmaceutical research and development experience, which Apellis expects will be a valuable asset to their complement pipeline.
Apellis Pharmaceuticals, Inc. Appoints Mikael Dolsten to Board of Directors, Effective March 1, 2026
Apellis Pharmaceuticals, Inc. announced the appointment of Mikael Dolsten, M.D., Ph.D., to its board of directors, effective March 1, 2026. Dr. Dolsten brings extensive experience from his 16-year tenure as chief scientific officer at Pfizer, where he oversaw the approval of numerous medicines and vaccines. He also holds various board positions in public and private companies and serves as a senior advisor to several financial groups.
Apellis Pharmaceuticals Adds Mikael Dolsten to Board
Apellis Pharmaceuticals (APLS) has appointed Mikael Dolsten, M.D., Ph.D., as an independent Class I director, effective March 1, 2026. Dolsten will receive equity-based compensation structured to align his interests with long-term shareholder value. An analyst has rated APLS stock a Buy with a $48.00 price target, while TipRanks' AI Analyst, Spark, rates it as Neutral, noting improved financial performance but cautioning about weak technical trends and a high P/E ratio.
Apellis Pharmaceuticals appoints Mikael Dolsten to board of directors By Investing.com
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) announced the appointment of Mikael Dolsten, M.D., Ph.D., to its board of directors as a Class I director, effective March 1, 2026. Dr. Dolsten will receive compensation including an option to purchase company shares and restricted stock units (RSUs), with vesting schedules tied to his service and potential change of control. This announcement follows recent news of Apellis's Q4 2025 earnings exceeding forecasts and an increased price target from H.C. Wainwright for its product Syfovre.
Mikael Dolsten joins Apellis Board as Class I director
Apellis Pharmaceuticals (APLS) has appointed Mikael Dolsten as a Class I director, effective March 1, 2026. Dolsten will receive compensation similar to other non-employee directors, including a stock option and restricted stock units, and has been deemed independent under Nasdaq rules. This appointment was made based on the recommendation of the Nominating and Corporate Governance Committee.
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
Apellis Pharmaceuticals, Inc. announced that Mikael Dolsten, M.D., Ph.D., has joined its board of directors. Dr. Dolsten previously served over 16 years as chief scientific officer at Pfizer, overseeing more than 36 regulatory approvals for medicines and vaccines. His extensive experience in pharmaceutical research and development is expected to be a valuable asset to Apellis as it continues to advance its complement pipeline.
Pfizer veteran who led R&D for 16 years joins Apellis board
Apellis Pharmaceuticals (Nasdaq: APLS) has announced that Mikael Dolsten, former chief scientific officer and president of worldwide R&D at Pfizer, has joined its board of directors. Dolsten brings over 16 years of experience, during which he oversaw the regulatory approval of more than 36 medicines and vaccines, and his expertise is expected to significantly benefit Apellis's complement-focused pipeline. This appointment aims to strengthen the company's research and development capabilities and strategic insight.
